George Fahed, MD
Pulmonary Disease · Ponce, PRNPI 1003850397
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Bayer at 43.9% of the total. Reporting peaked in 2019 at $8,456 and has fallen 71.0% since, to $2,454 in 2025. Among pulmonary disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 252 payments — averaging $64.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$7K
- AstraZeneca$2K
- GSK$2K
- Jazz Pharmaceuticals Inc.$1K
- United Therapeutics Corporation$771
- Merck$594
- plus $3K from 19 others
What the payments were for
- Speaking & faculty fees$5,87336%
- Travel & lodging$3032%
- Food & beverage$9,63159%
- Education$4333%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 29 | $7,126 |
| AstraZeneca | 83 | $2,486 |
| GSK | 33 | $1,715 |
| Jazz Pharmaceuticals Inc. | 21 | $1,003 |
| United Therapeutics Corporation | 13 | $771 |
| Merck | 10 | $594 |
| Boehringer Ingelheim | 13 | $592 |
| Harmony Biosciences LLC | 9 | $441 |
| Sanofi | 10 | $327 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $237 |
| Actelion Pharmaceuticals US, Inc. | 2 | $164 |
| E.r. Squibb & Sons, L.L.C. | 1 | $124 |
| Johnson & Johnson | 2 | $105 |
| Mallinckrodt Hospital Products Inc. | 1 | $99 |
| Mallinckrodt Enterprises LLC | 1 | $95 |
| Sanofi-aventis U.S. LLC | 3 | $71 |
| Genentech USA, Inc. | 3 | $63 |
| Viatris Specialty LLC | 2 | $55 |
| Mylan Specialty L.p. | 2 | $50 |
| Medtronic | 1 | $33 |
| Shire North American Group Inc | 2 | $28 |
| Amgen | 1 | $24 |
| Mylan LLC | 1 | $16 |
| PBG Puerto Rico LLC | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,239 in reported general payments places this provider in the 90th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 261 | $3,612,604 |
| OfevNintedanib Esylate | 34 | $305,920 |
| Tyvaso DpiTreprostinil | 12 | $277,722 |
| Fasenra PenBenralizumab | 41 | $238,080 |
| Dupixent PenDupilumab | 58 | $221,512 |
| TezspireTezepelumab-Ekko | 47 | $201,233 |
| OpsumitMacitentan | 12 | $148,591 |
| Humira(Cf) PenAdalimumab | 19 | $131,214 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 212 | $104,513 |
| NucalaMepolizumab | 26 | $94,843 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $89,556 |
| Dupixent SyringeDupilumab | 18 | $68,422 |
| Spiriva RespimatTiotropium Bromide | 104 | $55,335 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 58 | $37,973 |
| Breo ElliptaFluticasone/Vilanterol | 88 | $37,843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $7,126 | $3,612,604261 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $592 | $474,665368 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,486 | $270,371209 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,715 | $242,777292 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $164 | $148,59112 claims |
| MerckBelsomra | $594 | $4,91111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Ponce
- Domingo Chardon FelicianoPonce$45K
- Giovanni Veloz IrizarryPonce$11K
- Dev Boodoosingh CasianoPonce$10K
- Jesse Aleman-OrtizPonce$10K
- Keren Mendez RamirezPonce$8K
- Hector Puig-RamirezPonce$8K
- Sandra Galarza-VargasPonce$7K
- Ilean Lamboy HernandezPonce$5K
- Eugenio Rivera RiosPonce$3K
- Manuel Morell CataquetPonce$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.